Health TrialsbyHealthPanel

Low Risk Myelodysplastic Syndromes

3

Review clinical trials related to Low Risk Myelodysplastic Syndromes. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Phase I study with dose-escalation and expansion evaluating the safety and efficacy of oral Arsenic (ATO) in low-risk Myelodysplastic Syndromes having failed to Erythropoiesis Stimulating Agents and Luspatercept (or ineligible for the latter).

Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Groupe Francophone des MyelodysplasiesUpdated: Sep 10, 2026Locations: 3
Eligibility criteria

Myelodysplastic syndrome according to WHO (World Health Organization) 2022 class... [+18]

Severe infection or any uncontrolled severe condition [+12]

Read more
Status: Recruiting

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)

Participants needed: 86
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Rigel PharmaceuticalsUpdated: Aug 10, 2026Locations: 15
Eligibility criteria

Patient must be ≥ 18 years of age at the time of signing the informed consent. [+13]

Prior treatment for MDS (i.e., TPOs, EPOs, luspatercept, HMAs) concluded < 4 wee... [+15]

Read more
Status: Recruiting

Transfusion in Lower Risk MDS Patients: Predictors of Adequacy of Transfusion and Quality of Life in Lower Risk MDS

Observational study to evaluate changes in quality of life (QoL) in patients diagnosed with low risk MDS who are red blood cell (abc) transfusion dependent. Changes in QoL will be correlated with patient cardiorespiratory function. Cardiac biomarkers and plasma cytokines will also be evaluated.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Fundación para la Investigación Biosanitaria del Principado de AsturiasUpdated: Sep 27, 2024Locations: 1
Eligibility criteria

They must be able to understand the study procedures, comply with them, and cons... [+5]

Subject undergoing any of the following treatments: azacitidine, decitabine, ven... [+12]

Read more